Akorn to pay $7.9M to resolve allegations of fraudulent billingAkorn caused Medicare Part D to pay for three Akorn generic drugs that were no longer eligible for Medicare coverage. Novartis to petition U.S. Supreme Court to uphold validity of Gilenya dosing regimen patentNovartis said that it intends to vigorously defend the validity of the patent and is considering all available options. Coherus BioSciences to launch Lucentis biosimilar Cimerli is the first and only FDA-approved biosimilar interchangeable with Lucentis (ranibizumab injection). AllianceRx Walgreens Pharmacy reduces annual patient prescription costs by $6M Clinical audit programs prevent waste, improve adherence, reduce spend and provide outcomes data, the company said. Hikma intros 2 injectables The company is offering bortezomib for injection 3.5 mg and ulvestrant injection 250 mg/5 ml. Walgreens Boots Alliance takes full acquisition of Shields Health Solutions WBA is acquiring the remaining 30% stake of Shields (approximately 35% on a fully diluted basis) for approximately $1.37 billion. Bausch Health responds to Norwich Pharmaceuticals’ tentative FDA nod for rifaximin Xifaxan 200 mg is indicated for travelers' diarrhea and currently contributes less than 1% of Salix’s revenues. McKesson to acquire Rx Savings Solutions The acquisition aligns with McKesson’s strategic growth focus by connecting biopharma and payer services to patients, the company said. Dr. Reddy’s debuts generic Revlimid Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5-mg and 20-mg strengths. Albertsons, WinnCompanies bring essential services to affordable housing communities Albertsons is working with WinnCompanies to provide grocery, prescription and vaccination resources to seniors and families. First Previous 108 109 110 111 112 Next Last
